Arivin therapeutics is an innovative biotech company established in Finland, that is developing the next generation of anti-toxin strategies to tackle one of the biggest global health problems we currently face: resistant bacterial infections. Antimicrobial resistance already results in huge societal and economic losses, 1,27 million directly attributable deaths, and an estimated $15 billion in associated healthcare costs.
At Arivin, we are developing novel strategies that directly target the bacterial properties that cause inflammatory responses in the body: bacterial toxins and biofilm. This novel strategy dramatically reduces inflammatory response to the infection and strengthens the immune system to fight off the bacterial infection. The treatment avoids the development of bacterial resistance, enabling unique commercial opportunities; rapid resistance is a key bottleneck for the development of antibiotic therapies.
